The President of Diabetes Quebec, Serge Langlois, visited in Abitibi-Témiscamingue to raise awareness about the negative impact of modern lifestyle on health. An estimated 650 to 000 the number of diabetics in Quebec. Of these, approximately 200 000 are unaware of their condition. Diabetes is yet one of the leading causes of blindness, amputations and kidney failure, in addition to representing an important factor in cardiovascular disease. The latest figures dénombrent not less than 6,900 diabetics in Abitibi-Témiscamingue aged 20 and over. Aboriginal people are also at particular risk of developing the disease. Currently, 14% of area youth are obese, which gives the region the grim results of the third largest region of Quebec. However, obesity is an important factor in the onset of diabetes, whose prevalence is increasing among children and adolescents. For Serge Langlois, it is necessary to go back at our lifestyle. "The pace of modern life, often associated with progress, is very unhealthy," says he. "It is not necessary to run 10 miles every day to be healthy. Simply walk, while minimal attention to our diet, "says Langlois. In his lecture, President of Diabetes Québec has shown some examples, like a street photographed 100 years ago, and even today. Formerly, there were people everywhere in the picture, today, no one, but we see a multitude of cars. "I do not need to get rid of his car, I only say that it is easy to walk ten or fifteen minutes and you can choose smaller portions when feeding. Why take the biggest popcorn movie, "says he.
Tuesday, October 6, 2009
THE CREUSOT: Diabetes and heart and ... everyday life, Saturday at ALTO
Diabetes is becoming a worrying fact, related to the increase of overweight and physical inactivity. The Diabetes Prevention Network (2000 members) is to improve the overall care of people with diabetes, in partnership with health professionals and members of the municipalities. It offers interactive workshops proximity, diet, physical activity, groups of words ... etc ... Each year the General Assembly shall meet all its members and invites anyone interested in this disease to attend conferences information and learn from pharmaceutical innovations on the supervision and treatment of diabetes. The network teams and the Division of Diabetes will be available for visitors to discuss diet, blood pressure, footwear, and physical activity in attractive displays. This year, Dr. Louis Labbe diabetologist will address the theme "Diabetes and heart" and Dr Hermione Agopian diabetologist, "Diabetes and everyday life" with Sophie TRILLEAUD of the French Association of Diabetic which will be discussed difficulties in life every day: work, license, insurance ...
DIABEO: DIABETES MANAGED BY TELEMEDICINE
Today, telemedicine 'down the street, with the first Diabéo example, a tool for telemedicine to benefit patients with type 1 diabetes (IDDM absolute). An innovative device which meets all the requirements expected: it's tele-assistance, tele-surveillance, tele-consultation and tele-expertise.
Telemedicine is a concept developed to allow medical teams to provide them from city to city, region to region, to exchange information, discuss remote case of patients requiring a multidisciplinary approach to also allow physicians to require isolated Notice of a hospital specializing in one case, exchange and comment also images. It is obvious that the emergence of Internet has facilitated and accelerated this type of remote exchange.
It must be said that this example is striking because the initiatives are still few in the field of remote monitoring of a chronic condition. This initiative is a combination of work CERITD, Center for Studies and Research for Intensified Treatment of Diabetes, and Voluntis, creator of the software platform for e-health medpassport. They have developed an innovative device that meets the requirements expected: it's tele-assistance, tele-surveillance, tele-consultation and tele-expertise, the prefix "tele" takes its full meaning here, since it means (in Greek): Remote!
What was the problem? Answer: the constraints of chronic insulin therapy. Diabetes management is entrusted to the patient, ie multiple daily checks of blood glucose and multiple insulin injections. These constraints do not always facilitate the daily life and some people may feel isolated with their problems without support from their doctor.
Diabéo, created by clinicians and specialists in medical informatics, is a telemedicine solution for the monitoring of type 1 diabetes, presented by its designers as a real tool for therapeutic education (the concept evolving current) and d 'decision support, to empower the diabetes without that one has the impression that he must make do without the doctor. Diabéo is a software functional insulin downloaded on a phone-PDA and using the Internet channel through the operator Orange Healthcare. It is simple to use, which is essential if we want to extend and improve self-management of his illness by the patient. The transmission of data to the healthcare professional who follows the patient allows the constant monitoring of its biological control treatment, and can thus achieve a minimum ... teleconsultation for regular consultations assets are obviously necessary ... The study Télédiab 1 verified that Diabéo improves metabolic control in diabetic patients compared to a control group (not equipped). More importantly, this concept, its proponents say, can "reduce the distance between the practitioner and patient, to strengthen the management of patients, to optimize the working hours of nurses to meet increased demand for care without increase of resources. " This patient commits less spending by controlling blood glucose (lower frequency of complications), is supervised by a flexible, lightweight and above all do not feel the distance between him and his doctor, unless it is reluctant to computer ... and distance, which may exist in the psychology of these particular patients. The question obviously is, is it possible for type 2 diabetes? Certainly: Diabéo has opened prospects for a track that other diabetes, which requires, according to developers, complex treatment regimens by injection or pump, which is were the sole mode of treatment of type 1 but must be offered to Type 2 diabetes when oral (ADO) are no longer effective given the progression of type 2 to a similar stage of type 1. Law Hospital, health, patients and territories (HPST) includes an article on telemedicine. New information systems in the service of care and access to care, may contribute to the success of new issues of reforming the health system
Monday, October 5, 2009
Walk against Diabetes
The Society of poultry farmers, the town, several local associations and the European Center for the Study of Diabetes (CEED) organized on Sunday a large popular march against diabetes and medical research. Walking to say no to diabetes and to help researchers develop therapies. That's about the action day as they prepare for Sunday at Gerstheim. Organized on behalf of the European Center for the Study of Diabetes (CEED), this course will engage in fact, many volunteers from the community, very involved in the case. The free screenings for diabetes before and after the ride With the support of friendly blood donors, the Golden Age, music Concorde, ...
New data show that patients with type 2 diabetes who start therapy based insulin, combined with a single daily dose of NovoMix
New data show that patients with type 2 diabetes who start therapy based insulin, combined with a single daily dose of NovoMix ® 30 managed to reduce the HbA1c greater than treatment with insulin Glargine1 Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes initiating treatment with insulin combined a daily injection of NovoMix ® 30 (biphasic insulin aspart) are able to further reduce the HbA1cque patients starting with a daily injection of insulin glargine. The treatment with NovoMix ® 30 also resulted in blood glucose levels much lower after dinner and at bedtime, compared with those patients treated with insulin glargine.1
These new data from the study OnceMix in which 480 patients with type 2 diabetes inadequately controlled by oral antidiabetic agents, participated in 15 countries. They were randomly selected for treatment based on a single daily injection of NovoMix ® 30 or insulin glargine. In total, 433 patients completed the study. The average reduction HbA1centre the baseline and the end of the study after 26 weeks was -1.41% with NovoMix ® 30 cons -1.25% with insulin glargine.1
"This study shows that NovoMix ® 30 is a particularly effective option for patients with type 2 diabetes to start insulin," said Professor Krzysztof Strojek Medical University of Silesia in Zabrze, Poland, the main author of the study. "An additional advantage of using a premixed insulin as the ® 30 from the beginning is that it is very easy to intensify the treatment as and progression of diabetes, which is both practical Patient and important in terms of long-term control of disease. " At the end of treatment, mean HbA1c was 7.08% for NovoMix ® 30 against 7.23% for insulin glargine. In the evaluation of postprandial glucose control, we observed much lower levels of plasma glucose with NovoMix ® 30 after dinner and at bedtime (NovoMix ® 30 - insulin glargine -0.52 mmol / l, 95% CI [-1.02, -0.03], p = 0.04) and (NovoMix ® 30 - insulin glargine = -0.78 mmol / l, 95% CI [-1.25, -0.31] , p <0.01) respectively.1 The incidence of hypoglycaemic episodes was very low with both treatments (6.5 episodes / year for NovoMix ® 30 against 4.8 episodes / year for insulin glargine, with three major hypoglycemic episodes in each group) and the dose final day was also low and similar with both NovoMix ® 30 with insulin glargine (0.32 + / -0.22 units / kg for NovoMix ® 30 against 0.29 + / -0.19 units / kg for insulin glargine) .1
No relevant difference a clinical point of view between the treatment groups were found in markers of cardiovascular risk, waist circumference, body mass or satisfaction of treatment.The study is an attempt OnceMix "treat-to-target" open multinational multicentre, randomized and parallel. This study was conducted in a wide range of patient populations in 15 countries and is the first direct study between NovoMix ® 30 once-daily insulin glargine and once-daily.
During the period of run-ins ", titration of glimepiride and metformin was performed, followed by randomization to a treatment period of 26 weeks. Of a total of 480 patients in total were randomly selected, 433 completed the trial and participated in the final analysis. NovoMix ® 30 (biphasic insulin aspart) is a modern premixed insulin, dual-action, indicated for the treatment of diabetes mellitus, which contains both the rapid-acting insulin (30%) and intermediate-acting insulin (70%). The compound-action rapid NovoMix ® 30 begins to exert an effect on the absorption of glucose between 0 and 10 minutes2, it can be taken just before meals, while human insulin must be administered 15-30 minutes before . The adverse side effects observed in patients treated with NovoMix ® 30 mainly doses and due to the pharmacological effect of insuline2Chez patients with type 2 diabetes, a meta-analysis showed that while the risk diurnal hypoglycemic episodes increased overall in patients treated with NovoMix ® 30, it was associated with reduced risk of nocturnal hypoglycemic episodes and overall major hypoglycaemia compared with human insulin bi-phasic 30.2
Novo Nordisk is a healthcare and the global leader in diabetes care. In addition, Novo Nordisk has a dominant position in the market for hemostasis management, growth hormone and hormones for treating menopausal disorders. Novo Nordisk manufactures and markets products and pharmaceutical services that make a difference for patients, the medical profession and society. Novo Nordisk, whose headquarters are located in Denmark, employs approximately 28,500 employees in 81 countries and sells its products in 179 countries. The B shares in Novo Nordisk are listed on stock exchanges in Copenhagen and London. Its ADRs are listed on the NYSE under the symbol "NVO"
1 Franek E, et al. Launching a single daily dose of NovoMix 30 compared with insulin glargine in patients with type 2 diabetes inadequately controlled with oral antidiabetic agents - a randomized controlled trial. 45th annual meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29 to October 2, 2009. Oral Presentation # 213
These new data from the study OnceMix in which 480 patients with type 2 diabetes inadequately controlled by oral antidiabetic agents, participated in 15 countries. They were randomly selected for treatment based on a single daily injection of NovoMix ® 30 or insulin glargine. In total, 433 patients completed the study. The average reduction HbA1centre the baseline and the end of the study after 26 weeks was -1.41% with NovoMix ® 30 cons -1.25% with insulin glargine.1
"This study shows that NovoMix ® 30 is a particularly effective option for patients with type 2 diabetes to start insulin," said Professor Krzysztof Strojek Medical University of Silesia in Zabrze, Poland, the main author of the study. "An additional advantage of using a premixed insulin as the ® 30 from the beginning is that it is very easy to intensify the treatment as and progression of diabetes, which is both practical Patient and important in terms of long-term control of disease. " At the end of treatment, mean HbA1c was 7.08% for NovoMix ® 30 against 7.23% for insulin glargine. In the evaluation of postprandial glucose control, we observed much lower levels of plasma glucose with NovoMix ® 30 after dinner and at bedtime (NovoMix ® 30 - insulin glargine -0.52 mmol / l, 95% CI [-1.02, -0.03], p = 0.04) and (NovoMix ® 30 - insulin glargine = -0.78 mmol / l, 95% CI [-1.25, -0.31] , p <0.01) respectively.1 The incidence of hypoglycaemic episodes was very low with both treatments (6.5 episodes / year for NovoMix ® 30 against 4.8 episodes / year for insulin glargine, with three major hypoglycemic episodes in each group) and the dose final day was also low and similar with both NovoMix ® 30 with insulin glargine (0.32 + / -0.22 units / kg for NovoMix ® 30 against 0.29 + / -0.19 units / kg for insulin glargine) .1
No relevant difference a clinical point of view between the treatment groups were found in markers of cardiovascular risk, waist circumference, body mass or satisfaction of treatment.The study is an attempt OnceMix "treat-to-target" open multinational multicentre, randomized and parallel. This study was conducted in a wide range of patient populations in 15 countries and is the first direct study between NovoMix ® 30 once-daily insulin glargine and once-daily.
During the period of run-ins ", titration of glimepiride and metformin was performed, followed by randomization to a treatment period of 26 weeks. Of a total of 480 patients in total were randomly selected, 433 completed the trial and participated in the final analysis. NovoMix ® 30 (biphasic insulin aspart) is a modern premixed insulin, dual-action, indicated for the treatment of diabetes mellitus, which contains both the rapid-acting insulin (30%) and intermediate-acting insulin (70%). The compound-action rapid NovoMix ® 30 begins to exert an effect on the absorption of glucose between 0 and 10 minutes2, it can be taken just before meals, while human insulin must be administered 15-30 minutes before . The adverse side effects observed in patients treated with NovoMix ® 30 mainly doses and due to the pharmacological effect of insuline2Chez patients with type 2 diabetes, a meta-analysis showed that while the risk diurnal hypoglycemic episodes increased overall in patients treated with NovoMix ® 30, it was associated with reduced risk of nocturnal hypoglycemic episodes and overall major hypoglycaemia compared with human insulin bi-phasic 30.2
Novo Nordisk is a healthcare and the global leader in diabetes care. In addition, Novo Nordisk has a dominant position in the market for hemostasis management, growth hormone and hormones for treating menopausal disorders. Novo Nordisk manufactures and markets products and pharmaceutical services that make a difference for patients, the medical profession and society. Novo Nordisk, whose headquarters are located in Denmark, employs approximately 28,500 employees in 81 countries and sells its products in 179 countries. The B shares in Novo Nordisk are listed on stock exchanges in Copenhagen and London. Its ADRs are listed on the NYSE under the symbol "NVO"
1 Franek E, et al. Launching a single daily dose of NovoMix 30 compared with insulin glargine in patients with type 2 diabetes inadequately controlled with oral antidiabetic agents - a randomized controlled trial. 45th annual meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29 to October 2, 2009. Oral Presentation # 213
62% more cases of diabetes
In seven years, the number of people over 20 years diagnosed with diabetes in Abitibi-Témiscamingue jumped dazzling. One in 14 is now suffering from this chronic disease.
This indicates that a document produced by the Agency for Health and Social Services for Abitibi-Témiscamingue. Diabetes is an incurable disease characterized by a high concentration of sugar in the blood. In 2006-2007, a total of 8243 persons were diagnosed diabetes, compared to 5075 in 1999-2000, an increase of 62% in seven years. For guidance, the increase was slightly higher in Quebec, where the number increased by 69% during the same period. The Agency believes this growth is attributable in part to an aging population. Indeed, the prevalence of diabetes increases significantly as people age. However, the aging population is not strong enough to explain by itself such an increase. The resurgence of cases reflects the actual rise of diabetes. Several factors may influence the onset of the disease, such as heredity, obesity, physical inactivity, a diet rich in fat and belonging to certain ethnic groups such as indigenous. The percentage of people with diabetes varies significantly within the region. Compared to the provincial average, rates are much lower in Témiscamingue. In contrast, the territory of the Center for Health and Social Services (CSSS) eskers show a higher rate than the provincial average. It is possible that the data are underestimated for CSSS Témiscamingue due to the use by some of the people of this area of health services in Ontario. Conversely, the fact that the CSSS eskers has almost never been a shortage of doctors in recent years can possibly explain better screening, so a higher rate of diabetes. Due to this continued rise in diabetes, promoting healthy diet and active lifestyle, two aspects that reduce the risk of disease is therefore important.
This indicates that a document produced by the Agency for Health and Social Services for Abitibi-Témiscamingue. Diabetes is an incurable disease characterized by a high concentration of sugar in the blood. In 2006-2007, a total of 8243 persons were diagnosed diabetes, compared to 5075 in 1999-2000, an increase of 62% in seven years. For guidance, the increase was slightly higher in Quebec, where the number increased by 69% during the same period. The Agency believes this growth is attributable in part to an aging population. Indeed, the prevalence of diabetes increases significantly as people age. However, the aging population is not strong enough to explain by itself such an increase. The resurgence of cases reflects the actual rise of diabetes. Several factors may influence the onset of the disease, such as heredity, obesity, physical inactivity, a diet rich in fat and belonging to certain ethnic groups such as indigenous. The percentage of people with diabetes varies significantly within the region. Compared to the provincial average, rates are much lower in Témiscamingue. In contrast, the territory of the Center for Health and Social Services (CSSS) eskers show a higher rate than the provincial average. It is possible that the data are underestimated for CSSS Témiscamingue due to the use by some of the people of this area of health services in Ontario. Conversely, the fact that the CSSS eskers has almost never been a shortage of doctors in recent years can possibly explain better screening, so a higher rate of diabetes. Due to this continued rise in diabetes, promoting healthy diet and active lifestyle, two aspects that reduce the risk of disease is therefore important.
Diabète.Une Information Day Saturday
An information day "Stop the complications of diabetes will be held Saturday from 10 am to 18 pm at the Palais du Grand Large, Saint-Malo (35). Gerard Raymond, national president of the French Association of diabetes, will moderate the day free and open to all
Subscribe to:
Posts (Atom)